-
03/14/23 Health Advisory: Extensively Drug-Resistant Shigellosis
Advisory or Update, Communicable Disease and Immunization Update, Health Advisory, Infection Control, Notifiable Conditions, Provider Resources, TravelRequested actions Background Shigellosis is an acute enteric infection. It is an important cause of domestically acquired and travel-associated bacterial diarrhea in the United States. A low infectious dose makes Shigella bacteria easily transmitted from person to person. Consider shigellosis in the differential diagnosis of acute diarrhea, especially in people who: Shigellosis can be a mild, … 03/14/23 Health Advisory: Extensively Drug-Resistant Shigellosis
-
02/22/23 Health Advisory: Increase COVID-19 Treatment Access, Prescribing and Uptake
COVID-19 treatment is shown to reduce hospitalization. Yet it is under-used for high-risk patients with acute COVID-19. High-risk patients are: COVID-19 continues to cause 2,000 to 3,000 deaths each week in the United States. On Feb. 6, Washington State Department of Health (DOH) relaunched its free telehealth program. The program, in partnership with Color Health, … 02/22/23 Health Advisory: Increase COVID-19 Treatment Access, Prescribing and Uptake
-
02/13/23 Health Advisory: Shop Me Ca “Diep Bao Cream” Recalled
Actions requested Providers, facilities, parents and children should stop using Diep Bao Baby Skin Cream. Background On Feb. 1, 2023, Shop Me Ca recalled Diep Bao Skin Cream because of possible health risk. Shop Me Ca of Herndon, Virginia recalled its 10-gram tubes of “Diep Bao Cream” because they have the potential to be contaminated … 02/13/23 Health Advisory: Shop Me Ca “Diep Bao Cream” Recalled
-
02/03/23 Health Advisory: Multistate Cluster of Antibiotic Resistant Bacteria Associated with Artificial Tears
Actions requested Background Washington State Department of Health (DOH) and Centers for Disease Control and Prevention (CDC) are investigating a cluster of antibiotic-resistant infections that may be linked to artificial tears. The most frequently reported brand was EzriCare Artificial Tears, a preservative-free product dispensed in muti-dose bottles. These over-the-counter eye drops are sold widely in … 02/03/23 Health Advisory: Multistate Cluster of Antibiotic Resistant Bacteria Associated with Artificial Tears
-
Health Advisory: Updated bivalent COVID-19 boosters authorized for children 6 months to 5 years old
Advisory or Update, Communicable Disease and Immunization Update, COVID-19, Health Advisory, Immunizations, News and Alerts, Notifiable Conditions, Provider ResourcesEarlier this month, U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) expanded emergency use authorization (EUA) of Moderna and Pfizer-BioNTech bivalent vaccines for children 6 months and older. Updated (bivalent) COVID-19 booster vaccines are formulated to boost immunity against the original coronavirus strain and protect against the newer omicron … Health Advisory: Updated bivalent COVID-19 boosters authorized for children 6 months to 5 years old
-
12/19/22 Health Advisory: Antiviral Flu Treatment Interim Guidance
Be advised: Background Seasonal flu activity is high across the United States. Vaccination and antiviral treatment help prevent and control flu. U.S. Food and Drug Administration (FDA) approved 4 antivirals for early treatment of outpatients with flu: oseltamivir, baloxavir, zanamivir and peramivir. While FDA does not report shortages of oseltamivir in any of its forms, providers … 12/19/22 Health Advisory: Antiviral Flu Treatment Interim Guidance
-
12/19/22 Health Advisory: Newly Arrived Ukrainian Citizens’ Medical and Mental Health Needs
On April 21, 2022, President Biden announced a new Uniting for Ukraine (U4U) process to help Ukrainian citizens fleeing war come to the United States temporarily. As of Nov. 18, 2022: Newly arrived Ukrainian citizens have various medical and mental health needs. Resources
-
12/12/22 Health Advisory: COVID-19 Therapeutics Updates
Advisory or Update, COVID-19, Health Advisory, News and Alerts, Notifiable Conditions, Provider ResourcesBebtelovimab no longer authorized in the United States. On Nov. 30, 2022, U.S. Food and Drug Administration (FDA) revoked its Emergency Use Authorization (EUA) for bebtelovimab. Bebtelovimab is a monoclonal antibody used to treat COVID-19. FDA revoked the EUA because the drug lost efficacy against most SARS-CoV-2 variants currently circulating in the United States. Currently, … 12/12/22 Health Advisory: COVID-19 Therapeutics Updates
-
11/22/22 Health Advisory: Pediatric respiratory illness increasing in Western Washington
On Nov. 18, Washington State Department of Health (DOH) issued a high-level alert on a surge in respiratory syncytial virus (RSV) causing remarkable strain on pediatric emergency departments (EDs) and intensive care units (ICUs). This alert followed Centers for Disease Control and Prevention’s (CDC’s) Nov. 4 Health Alert Network (HAN) advisory on multiple viruses causing … 11/22/22 Health Advisory: Pediatric respiratory illness increasing in Western Washington
-
11/08/22 Health Advisory: Increased Respiratory Virus Activity
Advisory or Update, Health Advisory, Immunizations, Infection Control, News and Alerts, Provider Resources, SchoolsMultiple viruses are causing increased respiratory illness, especially among children, straining healthcare systems. Transmission of respiratory illnesses is increased in our communities. Schools report much higher absenteeism than normal for this time of year. Our hospital emergency departments are seeing many patients. This increase in illness early in respiratory illness season highlights the importance of … 11/08/22 Health Advisory: Increased Respiratory Virus Activity
-
10/27/22 Health Advisory: 2022–2023 Influenza Season Surveillance, Testing & Treatment
Advisory or Update, Health Advisory, Immunizations, Influenza, Influenza Update, Notifiable Conditions, Provider ResourcesRequested actions Vaccine This season’s updates in Centers for Disease Control and Prevention’s (CDC’s) Prevention and Control of Influenza (MMWR Vol. 71/No. 1): Surveillance Seasonal influenza surveillance starts in October and continues through April. We expect SARS-CoV-2 and influenza viruses will circulate simultaneously. To aid testing and treatment decisions, stay aware of local influenza and … 10/27/22 Health Advisory: 2022–2023 Influenza Season Surveillance, Testing & Treatment
-
10/19/22 Health Advisory: Updated bivalent COVID-19 boosters available to children 5 years or older
Communicable Disease and Immunization Update, COVID-19, Health Advisory, Immunizations, News and Alerts, Notifiable Conditions, Provider ResourcesCenters for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and Western States Scientific Safety Review Workgroup approved an age expansion for updated bivalent COVID-19 vaccine booster doses. The expansion allows children: 5–11 years old to get 1 booster dose of Pfizer pediatric updated bivalent COVID-19 vaccine. 6–17 years old to get 1 … 10/19/22 Health Advisory: Updated bivalent COVID-19 boosters available to children 5 years or older
-
10/03/22 Health Advisory: Severe cases of monkeypox among people with immune compromise
Advisory or Update, Communicable Disease and Immunization Update, Health Advisory, monkeypox, Notifiable Conditions, Provider ResourcesSince May 2022, the United States has seen more than 25,000 cases of monkeypox virus (MPV). Most cases are mild to moderate, but some people are at higher risk of severe illness: Under 8 years old. Immune compromise. Atopic dermatitis or eczema. Pregnant. Unsuppressed or uncontrolled human immunodeficiency virus (HIV). Of those currently diagnosed with MPV … 10/03/22 Health Advisory: Severe cases of monkeypox among people with immune compromise